Comparison

Recombinant Human SPARC His

Item no. CS-CSI20110B
Manufacturer Cell Sciences
Amount 50 ug
Category
Type Proteins
Specific against Human (Homo sapiens)
Host E.coli
Conjugate/Tag His
Purity >95% by SDS-PAGE and HPLC analyses.
Sequence MSYYHHHHHH DYDIPTTENL YFQGAMGSAP QQEALPDETE VVEETVAEVT EVSVGANPVQ VEVGEFDDGA EETEEEVVAE NPCQNHHCKH GKVCELDENN TPMCVCQDPT SCPAPIGEFE KVCSNDNKTF DSSCHFFATK CTLEGTKKGH KLHLDYIGPC KYIPPCLDSE LTEFPLRMRD WLKNVLVTLY ERDEDNNLLT EKQKLRVKKI HENEKRLEAG DHPVELLARD FE
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Similar products ON, cysteine-rich protein, osteonectin, BM-40, basement-membrane protein 40, secreted protein acidic and rich in cysteine
Available
Manufacturer - Category
Biomolecules
Storage Conditions
This lyophilized preparation is stable at 2-4C, but should be kept desiccated at -20C for long term storage. Upon reconstitution, the preparation is stable for up to one week at 2-4C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20C to -80C. Avoid repeated freeze/thaw cycles.
Molecular Weight
Approximately 34.0 kDa, a single non-glycosylated polypeptide chain containing 286 amino acids, with expression vector sequence (containing 6 x His tag).
Description
SPARC, an acronym for “secreted protein, acidic and rich in cysteine”, is also known as osteonectin or BM-40. It is the founding member of a family of secreted matricellular proteins with similar domain structure. The 303 amino acid, 43 kDa protein contains a 17 aa signal sequence, an N-terminal acidic region that binds calcium, a follistatin domain containing Kazal-like sequences, and a C-terminal extracellular calcium (EC) binding domain with two EF-hand motifs. SPARC is produced by fibroblasts, capillary endothelial cells, platelets and macrophages, especially in areas of tissue morphogenesis and remodeling. SPARC shows contextspecific effects, but generally inhibits adhesion, spreading and proliferation, and promotes collagen matrix formation. For endothelial cells, SPARC disrupts focal adhesions and binds and sequesters PDGF and VEGF. SPARC is abundantly expressed in bone, where it promotes osteoblast differentiation and inhibits adipogenesis.
Formulation
Lyophilized from a 0.2 um sterile filtered solution of PBS, pH 7.4.
Reconstitution
Centrifuge vial prior to opening. Add sterile distilled water or aqueous buffer to a concentration of 0.1-1.0 mg/mL. Further dilutions should be made in appropriate buffered solutions.
Endotoxin Level
Less than 1EU/ug of rHuSPARC as determined by LAL method.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 50 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close